ID   AK1C3_BOVIN             Reviewed;         323 AA.
AC   P05980; P52897;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   04-NOV-2026, entry version 156.
DE   RecName: Full=Aldo-keto reductase family 1 member C3 {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.- {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.210 {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.53 {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.62 {ECO:0000250|UniProtKB:P42330};
DE   AltName: Full=17-beta-hydroxysteroid dehydrogenase type 5;
DE            Short=17-beta-HSD 5;
DE   AltName: Full=3-alpha-HSD type II, brain;
DE   AltName: Full=3-alpha-hydroxysteroid dehydrogenase type 2 {ECO:0000250|UniProtKB:P42330};
DE            Short=3-alpha-HSD type 2 {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.357 {ECO:0000250|UniProtKB:P42330};
DE   AltName: Full=Chlordecone reductase homolog HAKRb;
DE   AltName: Full=Dihydrodiol dehydrogenase 3;
DE            Short=DD-3;
DE            Short=DD3;
DE   AltName: Full=Dihydrodiol dehydrogenase type I;
DE   AltName: Full=Prostaglandin F synthase {ECO:0000303|PubMed:2829166};
DE            Short=PGF {ECO:0000303|PubMed:2829166};
DE            Short=PGF synthase {ECO:0000303|PubMed:2829166};
DE            Short=PGFS {ECO:0000303|PubMed:1339268};
DE            EC=1.1.1.188 {ECO:0000269|PubMed:1339268};
DE   AltName: Full=Prostaglandin F synthase II {ECO:0000303|PubMed:1339268};
DE            Short=PGFSII {ECO:0000303|PubMed:1339268};
DE   AltName: Full=Prostaglandin-D2 11 reductase 1 {ECO:0000305|PubMed:2829166};
DE   AltName: Full=Testosterone 17-beta-dehydrogenase 5 {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.239 {ECO:0000250|UniProtKB:P42330};
DE            EC=1.1.1.64 {ECO:0000250|UniProtKB:P42330};
GN   Name=AKR1C3 {ECO:0000250|UniProtKB:P42330};
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Lung;
RX   PubMed=2829166; DOI=10.1073/pnas.85.1.11;
RA   Watanabe K., Fujii Y., Nakayama K., Ohkubo H., Kuramitsu S., Kagamiyama H.,
RA   Nakanishi S., Hayaishi O.;
RT   "Structural similarity of bovine lung prostaglandin F synthase to lens
RT   epsilon-crystallin of the European common frog.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:11-15(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND SUBUNIT.
RC   TISSUE=Liver;
RX   PubMed=1339268; DOI=10.1016/s0006-291x(05)80323-7;
RA   Kuchinke W., Barski O., Watanabe K., Hayaishi O.;
RT   "A lung type prostaglandin F synthase is expressed in bovine liver: cDNA
RT   sequence and expression in E. coli.";
RL   Biochem. Biophys. Res. Commun. 183:1238-1246(1992).
CC   -!- FUNCTION: Cytosolic aldo-keto reductase that catalyzes NADPH-dependent
CC       reduction of ketosteroids to hydroxysteroids. Displays broad substrate
CC       specificity with distinct positional and stereochemistry, primarily
CC       generating 17beta-hydroxysteroids, but also 3alpha- and 20alpha-
CC       hydroxysteroids. Produces potent androgens via classical and
CC       'backdoor'/alternative pathways. In the classical androgen metabolic
CC       pathway (biosynthesis of 5alpha-dihydrotestosterone (5alpha-DHT) via
CC       testosterone), catalyzes the reduction of delta4-androstenedione to
CC       form testosterone. In the 'backdoor' androgen metabolic pathway
CC       (biosynthesis of 5alpha-dihydrotestosterone (5alpha-DHT) via
CC       pregnanes), reduces androsterone to 5alpha-androstane-3alpha,17beta-
CC       diol preceding 5alpha-DHT secretion. Reduces 5alpha-DHT to less potent
CC       androgen 5alpha-androstane-3alpha,17beta-diol, likely regulating ligand
CC       availability for androgen receptors. May contribute to the metabolism
CC       of adrenal-derived androgen precursors. Reduces 11-keto-4-
CC       androstene-3,17-dione (11KA4) and 11-keto-5alpha-androstane-3,17-dione
CC       (11K-Adione) into potent androgens 11-ketotestosterone (11KT) and 11-
CC       ketodihydrotestosterone (11KDHT), respectively. In estrogen metabolism,
CC       catalyzes the conversion of estrone to potent estrogen 17beta-estradiol
CC       (By similarity). Acts as a prostaglandin (PG) F2alpha synthase.
CC       Displays 11-ketoreductase and 9,11-endoperoxide reductase activities
CC       and reduces PGD2 to 11beta-PGF2alpha and PGH2 to PGF2alpha
CC       (PubMed:1339268). Also displays retinaldehyde reductase activity toward
CC       9-cis-retinal. In vitro can efficiently catalyze bidirectional
CC       conversion between ketosteroids and hydroxysteroids using NADPH/NADP(+)
CC       or NADH/NAD(+) as cofactors. In vivo however, the reductase activity
CC       prevails since the major reducing cofactor NADPH inhibits NAD(+)-
CC       dependent oxidase activity (By similarity). In addition, it is able to
CC       reduce in vitro various carbonyl compounds like menadione,
CC       phenanthrenequinone and nitrobenzaldehyde (PubMed:1339268).
CC       {ECO:0000250|UniProtKB:P42330, ECO:0000269|PubMed:1339268}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin F2alpha + NADP(+) = prostaglandin D2 + NADPH +
CC         H(+); Xref=Rhea:RHEA:10140, ChEBI:CHEBI:15378, ChEBI:CHEBI:57404,
CC         ChEBI:CHEBI:57406, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.188; Evidence={ECO:0000269|PubMed:1339268};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:10142;
CC         Evidence={ECO:0000305|PubMed:1339268};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin F2alpha + NADP(+) = prostaglandin H2 + NADPH +
CC         H(+); Xref=Rhea:RHEA:45312, ChEBI:CHEBI:15378, ChEBI:CHEBI:57404,
CC         ChEBI:CHEBI:57405, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:1339268};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:45314;
CC         Evidence={ECO:0000305|PubMed:1339268};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 17beta-hydroxy steroid + NADP(+) = a 17-oxo steroid + NADPH
CC         + H(+); Xref=Rhea:RHEA:69284, ChEBI:CHEBI:15378, ChEBI:CHEBI:19168,
CC         ChEBI:CHEBI:35343, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:69286;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NADP(+) = a 3-oxosteroid + NADPH +
CC         H(+); Xref=Rhea:RHEA:34783, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.357; Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:34785;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=testosterone + NADP(+) = androst-4-ene-3,17-dione + NADPH +
CC         H(+); Xref=Rhea:RHEA:14981, ChEBI:CHEBI:15378, ChEBI:CHEBI:16422,
CC         ChEBI:CHEBI:17347, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.64;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:14983;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=androsterone + NADPH + H(+) = 5alpha-androstane-3alpha,17beta-
CC         diol + NADP(+); Xref=Rhea:RHEA:42156, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:36713, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42157;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + NADPH + H(+); Xref=Rhea:RHEA:42116,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42118;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3beta,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + NADPH + H(+); Xref=Rhea:RHEA:16297,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:18329,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.210;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:16299;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=androst-4-ene-3,11,17-trione + NADPH + H(+) = 17beta-
CC         hydroxyandrost-4-ene-3,11-dione + NADP(+); Xref=Rhea:RHEA:53484,
CC         ChEBI:CHEBI:2495, ChEBI:CHEBI:15378, ChEBI:CHEBI:34133,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53485;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstan-3,11,17-trione + NADPH + H(+) = 17beta-
CC         hydroxy-5alpha-androstan-3,11-dione + NADP(+); Xref=Rhea:RHEA:85531,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:34463, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:234448;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:85532;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3alpha-hydroxy-5alpha-androstan-11,17-dione + NADPH + H(+) =
CC         3alpha,17beta-dihydroxy-5alpha-androstan-11-one + NADP(+);
CC         Xref=Rhea:RHEA:85543, ChEBI:CHEBI:15378, ChEBI:CHEBI:34134,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:234449;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:85544;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NADP(+) = estrone + NADPH + H(+);
CC         Xref=Rhea:RHEA:24616, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.62;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24618;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NADP(+) = progesterone + NADPH
CC         + H(+); Xref=Rhea:RHEA:42112, ChEBI:CHEBI:15378, ChEBI:CHEBI:17026,
CC         ChEBI:CHEBI:28453, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42114;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin D2 + NADPH + H(+) = 11beta-prostaglandin F2 +
CC         NADP(+); Xref=Rhea:RHEA:45316, ChEBI:CHEBI:15378, ChEBI:CHEBI:57406,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:85173;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45317;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin D2-ethanolamide + NADPH + H(+) = 11beta-
CC         prostaglandin F2-ethanolamide + NADP(+); Xref=Rhea:RHEA:45308,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349,
CC         ChEBI:CHEBI:85174, ChEBI:CHEBI:85175;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45309;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=9-cis-retinol + NADP(+) = 9-cis-retinal + NADPH + H(+);
CC         Xref=Rhea:RHEA:54916, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:78272, ChEBI:CHEBI:78273;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:54918;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=testosterone + NAD(+) = androst-4-ene-3,17-dione + NADH +
CC         H(+); Xref=Rhea:RHEA:14929, ChEBI:CHEBI:15378, ChEBI:CHEBI:16422,
CC         ChEBI:CHEBI:17347, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         EC=1.1.1.239; Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NAD(+) = estrone + NADH + H(+);
CC         Xref=Rhea:RHEA:24612, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.62;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NAD(+) = progesterone + NADH +
CC         H(+); Xref=Rhea:RHEA:42108, ChEBI:CHEBI:15378, ChEBI:CHEBI:17026,
CC         ChEBI:CHEBI:28453, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + NADH + H(+); Xref=Rhea:RHEA:42004,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.53;
CC         Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = androsterone +
CC         NADH + H(+); Xref=Rhea:RHEA:42124, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:36713, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000250|UniProtKB:P42330};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=9,10-phenanthroquinone + NADPH + H(+) = phenanthrene-9,10-diol
CC         + NADP(+); Xref=Rhea:RHEA:63488, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:20814, ChEBI:CHEBI:37454, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000269|PubMed:1339268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63489;
CC         Evidence={ECO:0000305|PubMed:1339268};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=menadione + NADPH + H(+) = menadiol + NADP(+);
CC         Xref=Rhea:RHEA:63492, ChEBI:CHEBI:6746, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:28869, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:1339268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63493;
CC         Evidence={ECO:0000305|PubMed:1339268};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=4-nitrobenzaldehyde + NADPH + H(+) = 4-nitrobenzyl alcohol +
CC         NADP(+); Xref=Rhea:RHEA:63496, ChEBI:CHEBI:15378, ChEBI:CHEBI:41214,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:66926;
CC         Evidence={ECO:0000269|PubMed:1339268};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63497;
CC         Evidence={ECO:0000305|PubMed:1339268};
CC   -!- ACTIVITY REGULATION: Strongly inhibited by nonsteroidal anti-
CC       inflammatory drugs (NSAID) including flufenamic acid and indomethacin.
CC       Also inhibited by the flavinoid, rutin, and by selective serotonin
CC       inhibitors (SSRIs). The oxidation reaction is inhibited by low
CC       micromolar concentrations of NADPH. {ECO:0000250|UniProtKB:P42330}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=100 uM for prostaglandin D2 {ECO:0000269|PubMed:1339268};
CC         KM=0.13 uM for 9,10-phenanthroquinone {ECO:0000269|PubMed:1339268};
CC         KM=13 uM for menadione {ECO:0000269|PubMed:1339268};
CC         KM=8.3 uM for 4-nitrobenzaldehyde {ECO:0000269|PubMed:1339268};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:1339268}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P42330}.
CC   -!- PTM: The N-terminus is blocked. {ECO:0000269|PubMed:2829166}.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J03570; AAA30694.1; -; mRNA.
DR   EMBL; M86544; AAA30730.1; -; mRNA.
DR   PIR; A28396; A28396.
DR   PIR; E75572; JH0575.
DR   RefSeq; NP_001159696.1; NM_001166224.1.
DR   AlphaFoldDB; P05980; -.
DR   SMR; P05980; -.
DR   FunCoup; P05980; 104.
DR   PaxDb; 9913-ENSBTAP00000024086; -.
DR   PeptideAtlas; P05980; -.
DR   Ensembl; ENSBTAT00000024086.6; ENSBTAP00000024086.5; ENSBTAG00000022570.6.
DR   GeneID; 782922; -.
DR   KEGG; bta:782922; -.
DR   VEuPathDB; HostDB:ENSBTAG00000022570; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   GeneTree; ENSGT00940000153677; -.
DR   HOGENOM; CLU_023205_0_0_1; -.
DR   InParanoid; P05980; -.
DR   OMA; AAHYHKN; -.
DR   OrthoDB; 416253at2759; -.
DR   SABIO-RK; P05980; -.
DR   Proteomes; UP000009136; Chromosome 13.
DR   Bgee; ENSBTAG00000022570; Expressed in lung and 85 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0072582; F:17-beta-hydroxysteroid dehydrogenase (NADP+) activity; ISS:UniProtKB.
DR   GO; GO:0140169; F:3-alpha-hydroxysteroid 3-dehydrogenase [NAD(P)+] activity; ISS:UniProtKB.
DR   GO; GO:0047024; F:5-alpha-androstane-3-beta,17-beta-diol dehydrogenase (NADP+) activity; ISS:UniProtKB.
DR   GO; GO:0004032; F:aldose reductase (NADPH) activity; IBA:GO_Central.
DR   GO; GO:0047044; F:androstan-3-alpha,17-beta-diol dehydrogenase (NAD+) activity; IEA:UniProtKB-EC.
DR   GO; GO:0004303; F:estradiol 17-beta-dehydrogenase [NAD(P)+] activity; ISS:UniProtKB.
DR   GO; GO:0047086; F:ketosteroid monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0008753; F:NADPH dehydrogenase (quinone) activity; IEA:RHEA.
DR   GO; GO:0036131; F:prostaglandin D2 11-ketoreductase activity; ISS:UniProtKB.
DR   GO; GO:0047017; F:prostaglandin F synthase activity; EXP:UniProtKB.
DR   GO; GO:0036130; F:prostaglandin H2 endoperoxidase reductase activity; EXP:UniProtKB.
DR   GO; GO:0016229; F:steroid dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0047035; F:testosterone dehydrogenase (NAD+) activity; ISS:UniProtKB.
DR   GO; GO:0047045; F:testosterone dehydrogenase (NADP+) activity; ISS:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; IBA:GO_Central.
DR   CDD; cd19108; AKR_AKR1C1-35; 1.
DR   FunFam; 3.20.20.100:FF:000003; Aldo-keto reductase family 1 member C3; 1.
DR   Gene3D; 3.20.20.100; NADP-dependent oxidoreductase domain; 1.
DR   InterPro; IPR020471; AKR.
DR   InterPro; IPR044482; AKR1C.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR036812; NAD(P)_OxRdtase_dom_sf.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   PANTHER; PTHR11732; ALDO/KETO REDUCTASE; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; NAD(P)-linked oxidoreductase; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; Direct protein sequencing; Lipid metabolism; NADP;
KW   Oxidoreductase; Reference proteome.
FT   CHAIN           1..323
FT                   /note="Aldo-keto reductase family 1 member C3"
FT                   /id="PRO_0000124646"
FT   ACT_SITE        55
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250|UniProtKB:P14550"
FT   BINDING         20..24
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P17516"
FT   BINDING         50
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P17516"
FT   BINDING         166..167
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P17516"
FT   BINDING         190
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P17516"
FT   BINDING         270..280
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250|UniProtKB:P17516"
FT   SITE            84
FT                   /note="Lowers pKa of active site Tyr"
FT                   /evidence="ECO:0000250|UniProtKB:P14550"
FT   CONFLICT        10
FT                   /note="L -> F (in Ref. 2; AAA30730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        303
FT                   /note="I -> T (in Ref. 2; AAA30730)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        310
FT                   /note="K -> Q (in Ref. 2; AAA30730)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   323 AA;  36720 MW;  27E35CA47FB2FECC CRC64;
     MDPKSQRVKL NDGHFIPVLG FGTYAPEEVP KSEALEATKF AIEVGFRHVD SAHLYQNEEQ
     VGQAIRSKIA DGTVKREDIF YTSKLWCNSL QPELVRPALE KSLQNLQLDY VDLYIIHSPV
     SLKPGNKFVP KDESGKLIFD SVDLCHTWEA LEKCKDAGLT KSIGVSNFNH KQLEKILNKP
     GLKYKPVCNQ VECHPYLNQS KLLEFCKSHD IVLVAYAALG AQLLSEWVNS NNPVLLEDPV
     LCAIAKKHKQ TPALVALRYQ VQRGVVVLAK SFNKKRIKEN MQVFDFELTP EDMKAIDGLN
     RNIRYYDFQK GIGHPEYPFS EEY
//